DOCSLIB.ORG

SWEENEY-DISSERTATION-2020.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SWEENEY-DISSERTATION-2020.Pdf Copyright by Shannon Renee Sweeney 2020 The Dissertation Committee for Shannon Renee Sweeney Certifies that this is the approved version of the following dissertation: Elucidating metabolic vulnerabilities to improve outcomes in pediatric precursor B-cell acute lymphoblastic leukemia Committee: Stefano Tiziani, Supervisor Dean R. Appling Jennifer S. Brodbelt John DiGiovanni Marina Y. Konopleva Elucidating metabolic vulnerabilities to improve outcomes in pediatric precursor B-cell acute lymphoblastic leukemia by Shannon Renee Sweeney Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin May 2020 Dedication To my parents for always believing I was exceptional and inspiring me to prove them right. To my sisters – Lauren for keeping me grounded, Erin for making me want to fly – together you have taught me innumerable lessons. Thank you for teaching me how to mediate, negotiate, and above all, choose my battles. And to Nicholas, you make me better; none of this would have been possible without you. Acknowledgements I will be forever grateful and indebted to the many people who have guided me with endless encouragement and unwavering support. The most incredible tribe of brilliant women – Dr. Nathalie Muñoz, Dr. Maria José Romo Palafox, Dr. Gloria Cecilia Galván, Dr. Lauren D. Mangini, Dr. Deborah Salvo Domínguez, and soon to be doctors, Diana E. Gutierrez Lopez and Amy R. Nichols. It took me a while to find you, but in the end, your timing was impeccable. My lab family – Dr. Renu Pandey, Xiyuan Lu, Jennifer Chiou, Meghan Collins, Paul Gries, and Lavender Hackman. Thank you for sharing your gifts and being on this journey with me. Dr. Enrique Sentandreu, thank you for mentoring me long beyond our time together at the bench. Your guidance has been one of the greatest gifts. Dr. Alessia Lodi, thank you for your insightful observations, computational magic, and ability to visualize data so beautifully. To my committee members, I acknowledge that truly none of this is possible without you; thank you for sharing your precious time and insights with me. Last, but certainly not least, deepest gratitude to my advisor, Dr. Stefano Tiziani, for endlessly encouraging me to find my passion and realize my potential. v Abstract Elucidating metabolic vulnerabilities to improve outcomes in pediatric precursor B-cell acute lymphoblastic leukemia Shannon Renee Sweeney, PhD The University of Texas at Austin, 2020 Supervisor: Stefano Tiziani Cancer continues to be the leading cause of disease-related death in children. Improving treatment protocols and outcomes for pediatric leukemia patients is of critical importance as acute lymphoblastic leukemia (ALL) accounts for 25% of all childhood cancers. ALL five-year relative survival rates have improved significantly in recent decades. However, many survivors suffer severe chronic physiological and psychological health problems, as well as poor social and economic outcomes. These consequences exemplify the continuing need to develop targeted, less toxic alternative therapeutics. Metabolomics, an emerging tool for precision medicine, can be used to analyze intracellular and extracellular environments, metabolic response to treatment, and pathway regulation in order to expand our understanding of the molecular mechanisms that drive pediatric cancer biology and identify and evaluate novel therapeutics. This study applied metabolomics approaches to precursor B-cell ALL (BCP-ALL) which accounts for 80% of ALL cases in children and adolescents. First, high-throughput screening (HTS) was used to identify a synergistic combination of non-toxic therapeutic alternatives to chemotherapy. Metabolomics and metabolic flux analyses of dimethylaminoparthenolide (DMAPT) and vi shikonin (SHK) in BCP-ALL showed changes in amino acid, antioxidant, TCA cycle, and nucleotide metabolism. The shunting of glycolytic intermediates and glutaminolysis- related metabolites to support proliferation was inhibited by DMAPT and SHK leading to apoptosis in BCP-ALL cells. Second, bone marrow-derived leukemia cells were collected from pediatric BCP-ALL patients at diagnosis. Stratifying patients by cytogenetic anomalies yielded unique metabolic profiles. Aberrations at the IGH locus are associated with poor outcomes, but no clear therapeutic targets have been identified. Assessment of individual metabolites indicated that amino acids, amino acid-related compounds, and some sugars were more abundant in patients with IGH locus aberrations. Phosphatidylcholines, phosphatidylethanolamines, and polar compounds involved in lipid metabolism were also increased, while nucleotides, diglycerides, and triglycerides were decreased in the IGH group. Pathway interrogation confirmed metabolic dysregulation. HTS indicated IGH mutant sensitivity to HSP, proteasome, mTOR, and HDAC inhibitors. Together, these analyses indicate the flexibility and utility of metabolomics to elucidate the underlying biology of pediatric leukemia and evaluate novel therapeutics to improve quality of life and long-term outcomes for childhood leukemia patients and adult survivors. vii Table of Contents List of Tables ..................................................................................................................... xi List of Figures ................................................................................................................... xii Chapter 1: Introduction ........................................................................................................1 1.1 Cancer ...................................................................................................................1 1.2 Pediatric cancer .....................................................................................................3 1.3 Leukemia ..............................................................................................................4 1.3.1 Background ............................................................................................4 1.3.2 Urgent need to improve long-term outcomes for pediatric leukemia survivors ....................................................................................................5 1.3.3 Risk stratification has reduced pediatric leukemia mortality .................6 1.3.4 Leukemia is characterized by significant genetic alterations ................7 1.4 Cancer as a disease of aberrant metabolism .........................................................8 1.5 Metabolomics......................................................................................................10 1.5.1 The short history of metabolomics ......................................................10 1.5.2 Nuclear magnetic resonance spectroscopy ..........................................12 1.5.3 Mass spectrometry ...............................................................................14 1.5.4 Technological advancements ...............................................................17 1.5.5 Integration of clinical parameters and metabolic profiling ..................18 Chapter 2: Identification of a synergistic combination of dimethylaminoparthenolide and shikonin alters metabolism and inhibits proliferation of pediatric precursor B- cell acute lymphoblastic leukemia ...............................................................................20 2.1 Abstract ...............................................................................................................20 2.2 Introduction .........................................................................................................21 2.3 Materials and methods ........................................................................................23 viii 2.3.1 Reagents and chemicals .......................................................................23 2.3.2 Cell culture ...........................................................................................24 2.3.3 High-throughput screening ..................................................................25 2.3.4 Combination screening ........................................................................26 2.3.5 Ultrahigh performance liquid chromatography-mass spectrometry (UPLC-MS) analysis ...............................................................................27 2.4 Results .................................................................................................................30 2.4.1 Natural product library (NPL) screening .............................................30 2.4.2 Metabolomics and metabolic flux analysis ..........................................35 2.5 Discussion ...........................................................................................................45 Chapter 3: Stratification of pediatric leukemia patients by combining clinical parameters and metabolic signatures to identify exploitable pathway dysregulation for a personalized therapeutic approach ......................................................................49 3.1 Abstract ...............................................................................................................49 3.2 Introduction .........................................................................................................50 3.3 Materials and methods ........................................................................................52 3.3.1 Reagents and
Load more

Recommended publications
  • Endothelin System and Therapeutic Application of Endothelin Receptor
    xperim ACCESS Freely available online & E en OPEN l ta a l ic P in h l a C r m f o a c l a o n l o r g u y o J Journal of ISSN: 2161-1459 Clinical & Experimental Pharmacology Research Article Endothelin System and Therapeutic Application of Endothelin Receptor Antagonists Abebe Basazn Mekuria, Zemene Demelash Kifle*, Mohammedbrhan Abdelwuhab Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia ABSTRACT Endothelin is a 21 amino acid molecule endogenous potent vasoconstrictor peptide. Endothelin is synthesized in vascular endothelial and smooth muscle cells, as well as in neural, renal, pulmonic, and inflammatory cells. It acts through a seven transmembrane endothelin receptor A (ETA) and endothelin receptor B (ETB) receptors belongs to G protein-coupled rhodopsin-type receptor superfamily. This peptide involved in pathogenesis of cardiovascular disorder like (heart failure, arterial hypertension, myocardial infraction and atherosclerosis), renal failure, pulmonary arterial hypertension and it also involved in pathogenesis of cancer. Potentially endothelin receptor antagonist helps the treatment of the above disorder. Currently, there are a lot of trails both per-clinical and clinical on endothelin antagonist for various cardiovascular, pulmonary and cancer disorder. Some are approved by FAD for the treatment. These agents are including both selective and non-selective endothelin receptor antagonist (ETA/B). Currently, Bosentan, Ambrisentan, and Macitentan approved
    [Show full text]
  • FY 2020 Results Conference Call and Webcast for Investors and Analysts
    FY 2020 results Conference call and webcast for investors and analysts 11 February 2021 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure
    [Show full text]
  • Zibotentan, an Endothelin a Receptor Antagonist, Prevents Amyloid-Я
    Journal of Alzheimer’s Disease 73 (2020) 1185–1199 1185 DOI 10.3233/JAD-190630 IOS Press Zibotentan, an Endothelin A Receptor Antagonist, Prevents Amyloid-␤-Induced Hypertension and Maintains Cerebral Perfusion Jennifer C. Palmera,1, Hannah M. Taylera,1, Laurence Dyera, Patrick G. Kehoea, Julian F.R. Patonb and Seth Lovea,∗ aTranslational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK bDepartment of Physiology, Faculty of Medical & Health Sciences, University of Auckland, New Zealand Accepted 25 November 2019 Abstract. Cerebral blood flow is reduced in Alzheimer’s disease (AD), which is associated with mid-life hypertension. In people with increased cerebral vascular resistance due to vertebral artery or posterior communicating artery hypoplasia, there is evidence that hypertension develops as a protective mechanism to maintain cerebral perfusion. In AD, amyloid-␤ (A␤) accumulation may similarly raise cerebral vascular resistance by upregulation of the cerebral endothelin system. The level of endothelin-1 in brain tissue correlates positively with A␤ load and negatively with markers of cerebral hypoperfusion such as increased vascular endothelial growth factor. We previously showed that cerebroventricular infusion of A␤40 exacerbated pre- existing hypertension in Dahl rats. We have investigated the effects of 28-day cerebral infusion of A␤40 on blood pressure and heart rate and their variability; carotid flow; endothelin-1; and markers of cerebral oxygenation, in the (normotensive) Wistar rat, and the modulatory influence of the endothelin A receptor antagonist Zibotentan (ZD4054). Cerebral infusion of A␤ caused progressive rise in blood pressure (p < 0.0001) (paired t-test: increase of 3 (0.1–5.6) mmHg (p = 0.040)), with evidence of reduced baroreflex responsiveness, and accumulation of A␤ and elevated endothelin-1 in the vicinity of the infusion.
    [Show full text]
  • Experimental Models of Prostate Cancer Bone Metastasis - Establishment, Characterization and Imaging of Xenograft Bone Metastasis Models
    Experimental Models of Prostate Cancer Bone Metastasis - Establishment, characterization and imaging of xenograft bone metastasis models - PhD thesis presented by Marta Garcia López To obtain the degree of PhD for the Universitat Autònoma de Barcelona (UAB) PhD thesis done at the Research Unit in Biomedicine and Translational and Pediatrics Oncology, at the Vall d’Hebron Research Institute, Vall d’Hebron Hospital, under the supervision of Drs. Jaume Reventós i Puigjaner, Andreas Doll and Juan Morote Robles Doctoral study in Biochemistry, Molecular Biology and Biomedicine. Universitat Autònoma de Barcelona, Faculty of Bioscience, Department of Biochemistry and Molecular Biology Universitat Autònoma de Barcelona, 2013 Dr. Jaume Reventós Puigjaner Dr. Andreas Doll Dr. Juan Morote Robles Marta Garcia López No entiendes realmente algo a menos que seas capaz de explicárselo a tu abuela. Albert Einstein Summary In industrialized countries, prostate cancer (PCa) is the most common malignancy in men, but mortality rates are much lower than those recorded in developing countries, reflecting benefits from advances in early diagnosis and effective treatment. However, the metastatic disease rather than the primary tumour is responsible for much of the resulting morbidity and mortality. Skeletal metastases occur in more than 70% of cases of late-stage of PCa and they confer a high level of morbidity, a 5-year survival rate of 25% and median survival of approximately 40 months. Though fractures and spinal cord compression are potential complications, the most common symptom of bone metastases is pain. Bone metastases from PCa lead to an accelerated bone turnover state that features pathological activation of both osteoblasts and osteoclasts.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Characterisation of Proendothelin-1 Derived Peptides and Evaluation of Their Utility As Biomarkers of Vascular and Renal Pathologies
    Characterisation of Proendothelin-1 Derived Peptides and Evaluation of Their Utility as Biomarkers of Vascular and Renal Pathologies Jale Yuzugulen A thesis submitted for the degree of Doctor of Philosophy (Ph.D) in the Barts and the London School of Medicine and Dentistry of the Queen Mary, University of London 2014 Centre for Translational Medicine & Therapeutics, William Harvey Research Institute, John Vane Science Centre Charterhouse Square London UK i Statement of originality I, Jale Yuzugulen, confirm that the research included within this thesis is my own work or that where it has been carried out in collaboration with, or supported by others, that this is duly acknowledged below and my contribution indicated. Previously published material is also acknowledged below. I attest that I have exercised reasonable care to ensure that the work is original, and does not to the best of my knowledge break any UK law, infringe any third party’s copyright or other Intellectual Property Right, or contain any confidential material. I accept that the College has the right to use plagiarism detection software to check the electronic version of the thesis. I confirm that this thesis has not been previously submitted for the award of a degree by this or any other university. The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author. Signature: [ ] Date: 10/03/2014 ii List of publications and abstracts arising from this thesis: 1. Yuzugulen J, Wood EG, Douthwaite JA, Villar IC, Patel NS, Jegard J, Montoya A, Cutillas P, Hartley O, Ahluwalia A, Corder R.
    [Show full text]
  • Guide to Prescription Drug Benefits — NF-681
    GUIDE TO PRESCRIPTION DRUG BENEFITS Capital BlueCross is an Independent Licensee of the BlueCross BlueShield Association TABLE OF CONTENTS 1 Contact Us — Phone Number — Website 2-3 Using Your Prescription Drug Benefit — Retail, Mail Order, and Specialty Pharmacy 4 Be a Wise Health Care Consumer/Know Your Formulary Options — Generic Preferred — Generic Non-preferred — Brand Preferred — Brand Non-preferred 5 Accessing Your Prescription Drug Information — Website Information 6 Online Tools 7-9 Preferred Medication List 10-11 Prior Authorization 12-13 Enhanced Prior Authorization (Step Therapy) 14-17 Drug Quantity Management Program 17 Generic Substitution Program 18-19 Accredo® Health Group, Inc./Specialty Medications (self-administered) — Getting Started — Specialty Medication List 20 Capital BlueCross Pharmacy Network 21 Drug Watch for 2014 — Generic — Specialty Guide to Prescription Drug Benefits Welcome to the Capital BlueCross prescription drug program. To help you understand how your prescription drug benefit works and how you can get the most out of your health care dollar, we have created this guide. If you need more information, please refer to your Certificate of Coverage, or visit our website at capbluecross.com. Contact Information Customer Service Visit the Web If you have questions about your prescription drug Visit the Capital BlueCross website at capbluecross benefit, contact CVS Caremark customer service at .com to learn more about your prescription drug 800.585.5794 (TTY: 866.236.1069). CVS Caremark benefit. There you can: pharmacists and customer service representatives — Download the most up-to-date versions of are available any time of the day, seven days a week. the Formulary, Preferred Medication List, Prior The CVS Caremark customer service team also offers Authorization Program, the Drug Quantity interpretive services in 140 languages, including in- Management Program, and other useful house, Spanish-speaking representatives.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • WHO Drug Information Vol. 20, No. 3, 2006
    WHO DRUG INFORMATION VOLUME 20• NUMBER 3 • 2006 RECOMMENDED INN LIST 56 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA WHO Drug Information Vol 20, No. 3, 2006 World Health Organization WHO Drug Information Contents Biomedicines and Vaccines Counterfeit taskforce launched 192 Fake artesunate warning sheet 193 Monoclonal antibodies: a special Resolution on counterfeiting 193 regulatory challenge? 165 Improving world health through regulation of biologicals 173 Regulatory Action and News Influenza virus vaccines for 2006–2007 Safety and Efficacy Issues northern hemisphere 196 Trastuzumab approved for primary Global progress in monitoring immuniza- breast cancer 196 tion adverse events 180 Emergency contraception over-the- Intracranial haemorrhage in patients counter 197 receiving tipranavir 180 Ocular Fusarium infections: ReNu Infliximab: hepatosplenic T cell MoistureLoc® voluntary withdrawal 197 lymphoma 181 Saquinavir: withdrawal of soft gel Lamotrigine: increased risk of non- capsule Fortovase® 197 syndromic oral clefts 181 Latest list of prequalified products and Biphosphonates: osteonecrosis of manufacturers 198 the jaw 181 Clopidogrel: new medical use 199 Enoxaparin dosage in chronic kidney Dronedarone: withdrawal of marketing disease 182 authorization 199 Terbinafine and life-threatening blood dyscrasias 183 Adverse reactions in children: why Recent Publications, report? 183 Hepatitis B reactivation and anti-TNF- Information and Events alpha agents 185 MSF issues ninth antiretroviral
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • WO 2011/089216 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 28 July 2011 (28.07.2011) WO 2011/089216 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) C07K 1/13 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 1/1 07 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/050821 HN, HR, HU, ID, J , IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 1 January 201 1 (21 .01 .201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1015 1465. 1 22 January 2010 (22.01 .2010) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, CENDIS PHARMA AS [DK/DK]; Tuborg Boulevard TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 12, DK-2900 Hellerup (DK).
    [Show full text]
  • WO 2017/151816 Al 8 September 2017 (08.09.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/151816 Al 8 September 2017 (08.09.2017) P O P C T (51) International Patent Classification: Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, C07D 495/04 (2006.01) A61P 3/00 (2006.01) California 94404 (US). YANG, Xiaowei; c/o Gilead A61K 31/519 (2006.01) A61P 3/06 (2006.01) Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). (21) International Application Number: PCT/US20 17/020271 (74) Agents: TANNER, Lorna L. et al; Sheppard Mullin Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto, (22) Date: International Filing California 94301-1479 (US). 1 March 2017 (01 .03.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (30) Priority Data: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 62/302,755 2 March 2016 (02.03.2016) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 62/303,237 3 March 2016 (03.03.2016) US KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (71) Applicant: GILEAD APOLLO, LLC [US/US]; 333 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, Lakeside Drive, Foster City, California 94404 (US).
    [Show full text]